Newsbenzinga
Supernus Pharmaceuticals Raises FY2026 Sales Guidance from $860.000M-$890.000M to $875.000M-$900.000M vs $877.738M Est
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…